Year All202420232022202120202019 May 31, 2024 Verve Therapeutics Announces Leadership Update May 30, 2024 Verve Therapeutics to Participate in Upcoming Investor Conferences May 08, 2024 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results May 07, 2024 Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 May 03, 2024 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Apr 02, 2024 Verve Therapeutics Announces Updates on its PCSK9 Program Mar 28, 2024 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Mar 01, 2024 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Feb 27, 2024 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results Feb 01, 2024 Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
May 08, 2024 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
May 07, 2024 Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
Feb 27, 2024 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 01, 2024 Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
